Medical News

RSS

Geospiza’s GeneSifter software chosen for managing Eurofins MWG Operon's DNA sequencing systems

Eurofins MWG Operon and Geospiza, today announced that Eurofins MWG Operon has selected Geospiza’s GeneSifter® Lab Edition software to manage its DNA sequencing systems and further enhance its market leading customer experience.

27 Oct 2009

K2M opens direct sales and distribution office in the United Kingdom

K2M, Inc., the spinal device company developing innovative solutions for the treatment of complex spinal pathologies, today announced the opening of a direct sales and distribution office in the United Kingdom. K2M’s expansion into the UK began in 2008 with the CE Mark clearance and successful introduction of its RANGE® Spinal System, MESA® Spinal System, DENALI® Spinal System, PYRENEES® Cervical Plate System, and ALEUTIAN® Interbody Systems.

27 Oct 2009

SDC-based hard surface disinfectant is effective against the 2009 H1N1

PURE Bioscience, creators of the patented silver dihydrogen citrate (SDC) antimicrobial, announced today that its SDC-based hard surface disinfectant is effective against the 2009 H1N1 and is included on the list published by the U.S. Environmental Protection Agency (EPA) of antimicrobial products effective against the 2009 H1N1 flu strain based on their effectiveness against other influenza A virus strains.

27 Oct 2009

First Japanese patient treated in Celsion’s global Phase III ThermoDox HEAT trial

Celsion Corporation and Yakult Honsha Co., Ltd. announced today that the first patient has been enrolled and treated in Japan as part of Celsion’s global Phase III ThermoDox HEAT trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer.

27 Oct 2009

Acumedspa Holdings implements AcuClaims for 100 % of insurance verification and billing services

Acumedspa Holdings, Inc., which owns and operates multiple Medical Spa locations throughout South Florida has agreed to begin using AcuClaims for 100 % of insurance verification and billing services.

27 Oct 2009

Aquatrove Biosciences announces positive results from Conceive Plus study

Aquatrove Biosciences, Inc. presented positive results from a study demonstrating that the technology used in Conceive Plus™ may assist trying to conceive couples. These data were recently presented at the 65th Annual Meeting of the American Society for Reproductive Medicine (ASRM).

27 Oct 2009

Pilot Diode Laser launched by The CAO Group

The CAO Group, Inc., the world’s top diode laser company, today unveiled the Pilot™ Diode Laser, an innovative surgical and therapeutic instrument that represents a breakthrough for veterinary surgical and therapeutic treatments.

27 Oct 2009

BJC HealthCare to purchase Solos Endoscopy's MammoView line of products

Solos Endoscopy, Inc. is pleased to announce that the Company has received purchase orders for its MammoView(TM) line of surgical endoscopy instruments from BJC HealthCare, St. Louis Missouri. BJC HealthCare is one of the largest nonprofit health care organizations in the United States, delivering services to residents primarily in the greater St. Louis, southern Illinois and mid-Missouri regions.

27 Oct 2009

Netpulse raises funds for development of its interactive entertainment platform

Netpulse, the only interactive media platform for fitness centers and active lifestyle consumers, announced today that it has secured $3.1 million in Series A funding led by Javelin Venture Partners with participation from DFJ Frontier.

27 Oct 2009

CryoLife granted FDA approval for BioFoam human clinical trial

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for the company's Investigational Device Exemption (IDE) to conduct a human clinical trial for its BioFoam® Surgical Matrix protein hydrogel technology.

27 Oct 2009

Hope for lung cancer patients

Lung cancer is the world's most common cancer, and an estimated 219,440 Americans are expected to be diagnosed this year. It is also estimated that lung cancer will cause 159,000 deaths in the United States this year - more than the total number of deaths resulting from breast, colon and prostate cancers combined.

27 Oct 2009

Alkermes commences ALKS 37 phase 1 clinical trial for the treatment of opioid-induced constipation

Alkermes, Inc. today announced the initiation of a phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the opioid agonist effects on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled study will assess the safety, tolerability and pharmacokinetic effects of a single oral administration of five doses of ALKS 37 in approximately 40 healthy volunteers.

27 Oct 2009

Interim results from FREEDOM study announced by NxStage Medical

NxStage Medical, Inc., a leading manufacturer of innovative dialysis products, today announced the latest interim results from its ongoing FREEDOM study. The FREEDOM data will be presented in posters at the American Society of Nephrology (ASN) Renal Week 2009, from October 27th to November 1st in San Diego.

27 Oct 2009

OrSense launches a non-invasive Hb measurement system for anemia screening

OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, announced today at the American Association of Blood Banks (AABB) Annual Meeting & TXPO, at New Orleans, the presentation of NBM-200, a non-invasive hemoglobin (Hb) measurement system for anemia screening in blood donation centers.

27 Oct 2009

Unifill ready-to-fill safety syringes to hit markets soon

Unilife Medical Solutions Limited today announced it has commenced the filing of international trademarks for Unifill™, which will become the market brand for its portfolio of ready-to-fill safety syringes.

27 Oct 2009

ImmunoCellular Therapeutics presents additional data from its ICT-107 Phase I clinical trial

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is focused on the development of novel immune-based cancer therapies, today announced additional data from its Phase I clinical trial evaluating ICT-107, the Company’s dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme (GBM).

27 Oct 2009

Technology Resources Group acquired by Camstar Systems

Camstar Systems, Inc., the leading provider of manufacturing and quality software solutions for the Life Sciences, Solar and High Tech industries, today announced that it has acquired Technology Resources Group, Asia's leading Systems Integrator in the Semiconductor, Solar and Electronics manufacturing industries.

27 Oct 2009

Economic Adviser Romer goes to bat for 'Cadillac tax,' ways to control costs

ABC News reports that Christina D. Romer, chair of the president's Council of Economic Advisers, "went to bat on Monday for a tax on high-priced insurance plans, the so-called 'Cadillac tax,' calling it 'probably the number one item that health economists across the ideological spectrum believe is likely to stem the explosion of health-care costs.'"

27 Oct 2009

AFL-CIO to push even harder for health reform, may bend on 'Cadillac tax'

AFL-CIO President Richard Trumka is "willing to consider a tax on high-value health insurance plans — something labor has vehemently opposed — if middle-class workers aren't hurt, The Associated Press reports. The flexibility is notable because "[l]abor leaders worry that workers would be affected even though lawmakers aimed the proposed tax at insurance plans offering the richest benefits" (Werner, 10/26).

27 Oct 2009

BioSphere submits an IDE to the FDA for its QuadraSphere Microsphere product

BioSphere Medical, Inc. – the leader in the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy – today announced the submission to the U.S. Food and Drug Administration (FDA) of an Investigational Device Exemption (IDE) application for a clinical trial for the use of BioSphere’s QuadraSphere® Microsphere product (QuadraSphere) to deliver the chemotherapeutic agent doxorubicin for the treatment of primary liver cancer.

27 Oct 2009